Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Tax Provisions (2020 - 2025)

UroGen Pharma's Tax Provisions history spans 6 years, with the latest figure at -$275000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 110.38% year-over-year to -$275000.0; the TTM value through Dec 2025 reached $78000.0, down 97.25%, while the annual FY2025 figure was $78000.0, 97.25% down from the prior year.
  • Tax Provisions reached -$275000.0 in Q4 2025 per URGN's latest filing, up from -$1.1 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $3.9 million in Q4 2023 to a low of -$1.1 million in Q3 2025.
  • Average Tax Provisions over 5 years is $557444.4, with a median of $201500.0 recorded in 2021.
  • The largest YoY upside for Tax Provisions was 2571.05% in 2025 against a maximum downside of 1258.24% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $1.1 million in 2021, then tumbled by 39.4% to $689000.0 in 2022, then soared by 459.36% to $3.9 million in 2023, then plummeted by 31.27% to $2.6 million in 2024, then tumbled by 110.38% to -$275000.0 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Tax Provisions are -$275000.0 (Q4 2025), -$1.1 million (Q3 2025), and $1.0 million (Q2 2025).